drugset / Trial / NCT01012219
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
RandomizedCrossoverDouble-blindTreatment
Summary
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-03
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niacin | Small molecule | 1000 mg | Oral |
| Subject | laropiprant | Small molecule | 20 mg | Oral |
| Subject | laropiprant | Small molecule | 40 mg | Oral |
| Background | Aspirin | Small molecule | 81 mg | Oral |
| Background | Clopidogrel | Small molecule | 75 mg | Oral |